Pathophysiology and therapeutic possibilities of calcitonin gene-related peptide in hypertension.

J Physiol Biochem

Departamento de Fisiología, Facultad de Medicina, Universidad Autónoma de Madrid, C/ Arzobispo Morcillo 4, 28029 Madrid, Spain. and 1II1 Citedra de Farmacologfa, Facultad de Medicina, Universidad de Buenos Aires.

Published: March 2006

Calcitonin gene related peptide (CGRP), a 37 amino acid neuropeptide, is the most potent vasodilator known. Participation of CGRP in hypertension and related diseases, such as preeclampsia or vasospasm after subarachnoid haemorrage, is one of the most studied topics. In this review we summarize the published roles of CGRP in pathophysiology of hypertension in humans and in experimental models. We also discuss the effects of direct administration of CGRP in the treatment of hypertension and of anti-hypertensive drugs that enhance the release or response of endogenous calcitonin gene-related peptide: angiotensin converting enzyme inhibitors, selective antagonists for the angiotensin II receptor, beta-blockers, magnesium sulphate for preeclampsia and rutaecarpine, as well as the possibilities using CGRP in gene therapy for prevention of vasospasm after subarachnoid haemorrage.

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF03165805DOI Listing

Publication Analysis

Top Keywords

calcitonin gene-related
8
gene-related peptide
8
vasospasm subarachnoid
8
subarachnoid haemorrage
8
cgrp
5
pathophysiology therapeutic
4
therapeutic possibilities
4
possibilities calcitonin
4
hypertension
4
peptide hypertension
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!